Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards

About this update from Palvella Therapeutics, Inc.

WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has been named the Healthcare & Life Sciences Company of the Year at the 2026 Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards. “We are incredibly honored to be recognized by PACT as Healthcare & Life Sciences Company of the Year,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “This recognition reflects the passion, commitment, and execution of the entire Palvella team as we work to advance novel therapies for patients living with serious, rare skin diseases and vascular malformations who currently have no FDA-approved treatment options. We are proud to be building Palvella in Greater Philadelphia alongside one of the country’s most dynamic and growing innovative life sciences communities.” The PACT Ecosystem Awards celebrate leading technology, healthcare, and life sciences companies that are shaping the future through innovation, entrepreneurship, and regional leadership. Award recipients are selected based on criteria including the development and advancement of innovative products, clinical and commercial progress, capital formation, and commitment to the Greater Philadelphia community and life sciences ecosystem. Companies considered for the Healthcare & Life Sciences Company of the Year award are evaluated on the strength of their proprietary products and development programs, ability to advance clinical and business milestones, success in raising capital, and potential impact on patients and the broader healthcare industry. About Palvella Therapeutics Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an init...

View stock analysis, news, and events for Palvella Therapeutics, Inc.